{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:49:24Z","timestamp":1788306564573,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"glaxosmithkline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s40121-021-00546-z","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T21:26:22Z","timestamp":1637184382000},"page":"249-262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Long-Term Mortality and State Financial Support in Invasive Meningococcal Disease\u2014Real-World Data Analysis Using the French National Claims Database (SNIIRAM)"],"prefix":"10.1007","volume":"11","author":[{"given":"Jing","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Bou\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Aris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard C.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"546_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2018.00321","author":"S Nadel","year":"2018","unstructured":"Nadel S, Ninis N. Invasive meningococcal disease in the vaccine era. Front Pediatr. 2018. https:\/\/doi.org\/10.3389\/fped.2018.00321.","journal-title":"Front Pediatr"},{"key":"546_CR2","unstructured":"World Health Organization (WHO) Meningitis. https:\/\/www.who.int\/health-topics\/meningitis#tab=tab_1. (accessed Mar 17, 2021)"},{"key":"546_CR3","unstructured":"European Centre for Disease Prevention and Control (ECDC) Factsheet about meningococcal disease. https:\/\/www.ecdc.europa.eu\/en\/meningococcal-disease\/factsheet. (accessed Mar 17, 2021)"},{"key":"546_CR4","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","volume":"37","author":"B Wang","year":"2019","unstructured":"Wang B, Santoreneos R, Giles L, et al. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37:2768\u201382. https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.020.","journal-title":"Vaccine"},{"key":"546_CR5","unstructured":"World Health Organization (WHO) Factsheet\u2014Meningococcal meningitis. 2018. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/meningococcal-meningitis (accessed Mar 17, 2021)"},{"key":"546_CR6","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/s1474-4422(12)70180-1","volume":"11","author":"RM Viner","year":"2012","unstructured":"Viner RM, Booy R, Johnson H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11:774\u201383. https:\/\/doi.org\/10.1016\/s1474-4422(12)70180-1.","journal-title":"Lancet Neurol"},{"key":"546_CR7","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","volume":"59","author":"F Martin\u00f3n-Torres","year":"2016","unstructured":"Martin\u00f3n-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59:S12\u201320. https:\/\/doi.org\/10.1016\/j.jadohealth.2016.03.041.","journal-title":"J Adolesc Health"},{"key":"546_CR8","doi-asserted-by":"publisher","first-page":"010409-09","DOI":"10.7189\/jogh.09.010409","volume":"9","author":"ME Peterson","year":"2019","unstructured":"Peterson ME, Li Y, Bita A, et al. Meningococcal serogroups and surveillance: a systematic review and survey. J Glob Health. 2019;9:010409\u201309. https:\/\/doi.org\/10.7189\/jogh.09.010409.","journal-title":"J Glob Health"},{"key":"546_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40273-013-0057-2","volume":"31","author":"A Anonychuk","year":"2013","unstructured":"Anonychuk A, Woo G, Vyse A, et al. The cost and public health burden of invasive meningococcal disease outbreaks: a systematic review. Pharmacoeconomics. 2013;31:563\u201376. https:\/\/doi.org\/10.1007\/s40273-013-0057-2.","journal-title":"Pharmacoeconomics"},{"key":"546_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jiph.2015.10.016","volume":"9","author":"S B\u00e9nard","year":"2016","unstructured":"B\u00e9nard S, Wright C, Voisine J, et al. Lifetime cost of meningococcal disease in France: scenarios of severe meningitis and septicemia with purpura fulminans. J Infect Public Health. 2016;9:339\u201347. https:\/\/doi.org\/10.1016\/j.jiph.2015.10.016.","journal-title":"J Infect Public Health"},{"key":"546_CR11","unstructured":"European Centre for Disease Prevention and Control (ECDC). Vaccine scheduler\u2014meningococcal disease: recommended vaccinations. 2021. https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1. (accessed Mar 25, 2021)"},{"key":"546_CR12","unstructured":"UK National Health Service Vaccination - Meningitis. 2021. https:\/\/www.nhs.uk\/conditions\/meningitis\/vaccination\/#:~:text=The%20meningitis%20B%20vaccine%20is,a%20booster%20at%201%20year. (accessed Mar 25, 2021)"},{"key":"546_CR13","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1080\/21645515.2020.1729030","volume":"16","author":"MK Taha","year":"2020","unstructured":"Taha MK, Gaudelus J, Deghmane AE, et al. Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries. Hum Vaccin Immunother. 2020;16:2518\u201323. https:\/\/doi.org\/10.1080\/21645515.2020.1729030.","journal-title":"Hum Vaccin Immunother"},{"key":"546_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228020","volume":"15","author":"L Huang","year":"2020","unstructured":"Huang L, Heuer OD, Jan\u00dfen S, et al. Clinical and economic burden of invasive meningococcal disease: evidence from a large German claims database. PLoS\u00a0One. 2020;15: e0228020. https:\/\/doi.org\/10.1371\/journal.pone.0228020.","journal-title":"PLoS\u00a0One"},{"key":"546_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","volume":"7","author":"KJ Olbrich","year":"2018","unstructured":"Olbrich KJ, M\u00fcller D, Schumacher S, et al. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7:421\u201338. https:\/\/doi.org\/10.1007\/s40121-018-0213-2.","journal-title":"Infect Dis Ther"},{"key":"546_CR16","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","volume":"26","author":"J Bezin","year":"2017","unstructured":"Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26:954\u201362. https:\/\/doi.org\/10.1002\/pds.4233.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"546_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1849518","author":"MK Taha","year":"2021","unstructured":"Taha MK, Weil-Olivier C, Bou\u00e9e S, et al. Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Hum Vaccin Immunother. 2021. https:\/\/doi.org\/10.1080\/21645515.2020.1849518.","journal-title":"Hum Vaccin Immunother"},{"key":"546_CR18","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.vaccine.2019.01.013","volume":"37","author":"S Scholz","year":"2019","unstructured":"Scholz S, Koerber F, Meszaros K, et al. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. Vaccine. 2019;37:1692\u2013701. https:\/\/doi.org\/10.1016\/j.vaccine.2019.01.013.","journal-title":"Vaccine"},{"key":"546_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jval.2020.09.004","volume":"24","author":"E Beck","year":"2021","unstructured":"Beck E, Klint J, Neine M, et al. Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24:91\u2013104. https:\/\/doi.org\/10.1016\/j.jval.2020.09.004.","journal-title":"Value Health"},{"key":"546_CR20","volume-title":"Flexible parametric survival analysis using stata: beyond the cox model","author":"P Royston","year":"2011","unstructured":"Royston P, Lambert PC. Flexible parametric survival analysis using stata: beyond the cox model. College Station: StataCorp LP; 2011."},{"key":"546_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/bf01644442","volume":"14","author":"H Kjersem","year":"1986","unstructured":"Kjersem H, Bohr V, Rasmussen N, et al. Mortality in the years following bacterial meningitis. Infection. 1986;14:55\u20139. https:\/\/doi.org\/10.1007\/bf01644442.","journal-title":"Infection"},{"key":"546_CR22","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00431-018-3192-0","volume":"177","author":"L Pickering","year":"2018","unstructured":"Pickering L, Jennum P, Ibsen R, et al. Long-term health and socioeconomic consequences of childhood and adolescent onset of meningococcal meningitis. Eur J Pediatr. 2018;177:1309\u201315. https:\/\/doi.org\/10.1007\/s00431-018-3192-0.","journal-title":"Eur J Pediatr"},{"key":"546_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009662","volume":"5","author":"C Roed","year":"2010","unstructured":"Roed C, Omland LH, Engsig FN, et al. Long-term mortality in patients diagnosed with meningococcal disease: a Danish nationwide cohort study. PLoS\u00a0One. 2010;5: e9662. https:\/\/doi.org\/10.1371\/journal.pone.0009662.","journal-title":"PLoS\u00a0One"},{"key":"546_CR24","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s40121-021-00468-w","volume":"10","author":"C Weil-Olivier","year":"2021","unstructured":"Weil-Olivier C, Taha M-K, Emery C, et al. Healthcare resource consumption and cost of invasive meningococcal disease in France: a study of the National Health Insurance Database. Infect Dis Ther. 2021;10:1607\u201323. https:\/\/doi.org\/10.1007\/s40121-021-00468-w.","journal-title":"Infect Dis Ther"},{"key":"546_CR25","unstructured":"Shen J, Begum N, Ruiz Garcia Y, et al. PD051\/#550: the long-lasting impact of invasive meningococcal disease (IMD)\u2014mapping the comprehensive range of sequelae in imd survivors. 2021. European Society for Paediatric Infectious Diseases Geneva, Switzerland"},{"key":"546_CR26","unstructured":"Nolte E, Knai C, Saltman RB. Assessing chronic disease management in European health systems. Assessing chronic disease management in European health systems: Concepts and approaches. European Observatory Health Policy Series. Copenhagen (Denmark): European Observatory on Health Systems and Policies \u00a9 World Health Organization 2014 (acting as the host organization for, and secretariat of, the European Observatory on Health Systems and Policies). 2014"},{"key":"546_CR27","unstructured":"European Association of Service Providers for Persons with Disabilities (EASPD) Social welfare systems across Europe. https:\/\/www.easpd.eu\/sites\/default\/files\/sites\/default\/files\/SensAge\/d4-social_welfare_systems_across_europe.pdf. (accessed May 25, 2021)"},{"key":"546_CR28","unstructured":"Sante Publique France Les infections invasives \u00e0 m\u00e9ningocoque en France en 2017 2017. https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-a-prevention-vaccinale\/infections-invasives-a-meningocoque\/documents\/bulletin-national2\/les-infections-invasives-a-meningocoque-en-france-en-2017. (accessed Sep 14, 2021)"},{"key":"546_CR29","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jinf.2019.12.008","volume":"80","author":"K Beebeejaun","year":"2020","unstructured":"Beebeejaun K, Parikh SR, Campbell H, et al. Invasive meningococcal disease: timing and cause of death in England, 2008\u20132015. J Infect. 2020;80:286\u201390. https:\/\/doi.org\/10.1016\/j.jinf.2019.12.008.","journal-title":"J Infect"}],"updated-by":[{"DOI":"10.1007\/s40121-021-00584-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000}}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00546-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-021-00546-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00546-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T17:38:11Z","timestamp":1644946691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-021-00546-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["546"],"URL":"https:\/\/doi.org\/10.1007\/s40121-021-00546-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40121-021-00584-7","asserted-by":"object"}]},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"assertion":[{"value":"29 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40121-021-00584-7","URL":"https:\/\/doi.org\/10.1007\/s40121-021-00584-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}